Checkpoint Therapeutics Stock
Your prediction
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 5.540% | -7.752% | -65.640% | -80.843% | -68.169% | -69.431% | -97.164% |
| Evolus Inc | -0.690% | 9.624% | 5.568% | -33.529% | 3.670% | -26.144% | -36.872% |
| Rhythm Pharmaceuticals | -0.680% | 2.740% | -6.250% | 30.435% | -19.786% | 368.750% | 390.196% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat